Scilex Holding

SCLX

United States

Scilex Holding Company is dedicated to advancing non-opioid therapies for pain management, aiming to provide safer alternatives in the context of the national opioid epidemic. Its commercial portfolio includes ZTlido® (lidocaine topical system) 1.8% for post-herpetic neuralgia, and it has a pipeline featuring late-stage candidates like SP-102 (SEMDEXA™) for lumbar radicular pain. The company leverages a combination of commercial execution and clinical development to capture value in the large and growing pain therapeutics market.

scilexholding.com

SCLX · Stock Price

USD 6.612.28 (-25.65%)

Market Cap: $47.1M

Historical price data

AI Company Overview

Pain ManagementNeurologyRheumatology

Technology Platform

Focuses on advanced formulation science and targeted drug delivery to develop non-opioid pain therapies, including novel topical systems and injectable viscous gels.

Pipeline

16 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
Lidocaine 1.8% + Placebo	Carpal Tunnel Syndrome	Approved
SP-102 + Placebo	Lumbosacral Radicular Pain	Phase 3
SP-103 + Placebo	Moderate to Severe Acute Lower Back Pain	Phase 2
SP-102	Lumbosacral Radicular Pain	Phase 2
ZTlido (Lidocaine Topical System) 1.8% + Salonpas (Lidocaine...	Healthy	Phase 1

Opportunities

The primary growth opportunity is the potential FDA approval and subsequent commercialization of SP-102 (SEMDEXA™) in the multi-billion dollar epidural steroid injection market.

Further opportunity lies in expanding the labels of its commercial products and advancing its earlier-stage pipeline candidates.

Risk Factors

Key risks include regulatory rejection or delay for SP-102, challenges in achieving market penetration against established generic competitors, potential future dilution from capital raises, and dependence on the strategic direction of majority-owner Sorrento Therapeutics.

Competitive Landscape

Scilex competes in the crowded pain management market against large pharma, specialty pharma, and generic manufacturers. Its differentiation strategy is based on developing novel, non-opioid formulations (like SEMDEXA) that aim to be first-in-class and offer clinical advantages over existing standard-of-care treatments.